MedTrace Logo

PSA Glycomics Assay for Early Detection of Prostate Cancer

NCT04393376 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-09-26

No results posted yet for this study

Summary

The principal aim of this pilot study is to test whether the PSA Glycomics Assay on urine and serum samples can provide insights regarding the disease state of patients with elevated PSA concentrations, as well as to accurately identify if the patient has prostate cancer and, in the case of prostate cancer, to determine its level of aggressiveness.

Conditions

Interventions

DIAGNOSTIC_TEST

PSA Glycomics Assay

PSA Glycomics Assay will be performed on urine and blood samples

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • Prof.dr. H.P. Beerlage

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2024-01-01
Completion
2025-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04393376 on ClinicalTrials.gov